Wiercinski Kwiecinski Baehr has advised Blirt’s shareholders on the sale of a 96% stake to Qiagen. Wardynski & Partners reportedly advised Qiagen on the deal.
Blirt is a company specializing in the industrial-scale production of recombinant proteins. The company also produces kits for isolating DNA and RNA and reagents for reverse transcription and real-time PCR.
Qiagen is an international biotech company and a provider of molecular insight solutions.
WKB’s team included Partners Jakub Jedrzejak and Marta Midloch, Managing Associate Tomasz Maslak, and Associates Joanna Ksepko and Anna Matsiyeuskaya.
Editor's Note: After this article was published, Wardynski & Partners confirmed it had advised Qiagen on the acquisition. The firm's team included Partners Marcin Pietkiewicz and Maciej Szewczyk and Senior Associates Katarzyna Jaroszynska and Bartosz Lewandowski.
